Dexcom Issues Statement on Recent Market Speculation

Rhea-AI Summary

DexCom, Inc. (NASDAQ:DXCM) has addressed recent media speculation regarding potential mergers and acquisitions. The company confirms it is currently not in active discussions about a merger transaction. This statement comes in the context of ongoing rumors and the approaching American Diabetes Association conference. DexCom's management emphasized their regular review of opportunities to enhance stockholder value but will not comment further on this matter unless circumstances change.

Positive

• Management actively reviews opportunities to enhance stockholder value.
• Strong leadership position in diabetes care technology.

Negative

• No active discussions regarding mergers may limit strategic growth opportunities.

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM) today issued the following statement in response to recent media and market speculation:

“Like many companies, Dexcom’s Board and management team regularly review opportunities to enhance stockholder value and create benefits for customers, including through mergers and acquisitions. It is generally our policy not to comment on rumors or speculation, however, in light of recent sustained media and market speculation as well as the upcoming American Diabetes Association conference, we wish to confirm that Dexcom is not in active discussions regarding a merger transaction at this time. We do not intend to comment further on this topic and we assume no obligation to make any further announcement or disclosure should circumstances change.”

About DexCom, Inc.

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220531005303/en/

Investor Relations Contact:

Sean Christensen

Senior Director – Investor Relations and Corporate FP&A

investor-relations@dexcom.com

(858) 200-0200

Media Contact:

James McIntosh

Head of Public Relations

james.mcintosh@dexcom.com

(619) 884-2118

Source: DexCom, Inc.

FAQ

What did DexCom say about merger speculation?

DexCom stated it is not in active discussions regarding a merger transaction.

What is the stock symbol for DexCom?

The stock symbol for DexCom is DXCM.

When is the next American Diabetes Association conference?

The specific date of the upcoming American Diabetes Association conference was not mentioned in the press release.